Sellas Life Sciences is trading 5.5% up at $14.14, with the gain appearing driven by trading activity and continued interest in the upcoming REGAL readout.
- No new company-specific announcement was identified for August 21, 2026.
- The latest official update was the August 11 second-quarter report, reiterating the Phase 3 REGAL trial’s planned final analysis after the 80th event.
- Volume was above the daily average, while biotechnology was declining.